AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-10. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Evolutionary dynamics: a mathematical model === According to the definition of a hypercycle, it is a nonlinear, dynamic system, and, in the simplest case, it can be assumed that it grows at a rate determined by a system of quadratic differential equations. Then, the competition between evolving hypercycles can be modelled using the differential equation:
Human Vapor (Japanese: ガス人間; Korean: 가스인간) is a 2026 science fiction crime thriller television series based on the 1960 tokusatsu film The Human Vapor by Ishirō Honda and Takeshi Kimura. A Japanese–South Korean co-production written by Yeon Sang-ho and Ryu Yong-jae and directed by Shinzo Katayama, the series stars Shun Oguri, Yu Aoi, Suzu Hirose, Kento Hayashi, Uta, and Yutaka Takenouchi. It is produced by Toho Studios and Wow Point, marking the first collaboration between Netflix and Toho, and was released on Netflix on July 2, 2026.
State law allows for the dispensing of the drugs/chemicals for lethal injection to the state's department of corrections without a prescription. However, states are still subject to DEA regulation with respect to lethal injection drugs.
Overall, Bagwell batted over .300 six times, had a career OBP of .408 (39th all-time), and had a slugging percentage of .540 (32nd all-time). He was elected to the Texas Sports Hall of Fame in 2005. In 2017, Bagwell was elected to the National Baseball Hall of Fame.
== Industrial and academic career == After receiving his PhD in organic chemistry from the University of Chicago (1981) under the direction of Emil T. Kaiser, DeGrado began work at DuPont as a research chemist, eventually becoming a senior director for small molecule therapeutics in DuPont Merck's medicinal chemistry department. In 1995 he moved to the University of Pennsylvania, where he was a professor in the biochemistry and biophysics department as well as an adjunct professor in the department of chemistry. Since 2011 he has been at the University of California, San Francisco School of Pharmacy, where he is the Toby Herfindal Presidential Professor of Entrepreneurship and Innovation. He is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases at UCSF.
Sources: en.wikipedia.org
=== Neuronal Control === The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain, which exert control over the alpha cells in the pancreas. The pancreas is controlled by both the sympathetic nervous system and the parasympathetic nervous system, although the method these two systems use to control the pancreas appears to be different. Sympathetic control of the pancreas appears to originate from the sympathetic preganglionic fibers in the lower thoracic and lumbar spinal cord. According to Travagli et al. "axons from these neurons exit the spinal cord through the ventral roots and supply either the paravertebral ganglia of the sympathetic chain via communicating rami of the thoracic and lumbar nerves, or the celiac and mesenteric ganglia via the splanchnic nerves. The catecholaminergic neurons of these ganglia innervate the intrapancreatic ganglia, islets and blood vessels..." The exact nature of the effect of sympathetic activation on the pancreas has been difficult to discern. However, a few things are known. It appears that stimulation of the splanchnic nerve lowers plasma insulin levels possibly through the action of α2 adrenoreceptors on beta cells. It has also been shown that stimulation of the splanchnic nerve increases glucagon secretion. Both of these findings together suggest that sympathetic stimulation of the pancreas is meant to maintain blood glucose levels during heightened arousal. Parasympathetic control of the pancreas appears to originate from the Vagus nerve.
The phenomenon of exonization also represents a special case of de novo gene birth, in which, for example, often-repetitive intronic sequences acquire splice sites through mutation, leading to de novo exons. This was first described in 1994 in the context of Alu sequences found in the coding regions of primate mRNAs. Interestingly, such de novo exons are frequently found in minor splice variants, which may allow the evolutionary "testing" of novel sequences while retaining the functionality of the major splice variant(s). Still, it was thought by some that most or all eukaryotic proteins were constructed from a constrained pool of "starter type" exons. Using the sequence data available at the time, a 1991 review estimated the number of unique, ancestral eukaryotic exons to be < 60,000, while in 1992 a piece was published estimating that the vast majority of proteins belonged to no more than 1,000 families. Around the same time, however, the sequence of chromosome III of the budding yeast Saccharomyces cerevisiae was released, representing the first time an entire chromosome from any eukaryotic organism had been sequenced. Sequencing of the entire yeast nuclear genome was then completed by early 1996 through a massive, collaborative international effort. In his review of the yeast genome project, Bernard Dujon noted that the unexpected abundance of genes lacking any known homologs was perhaps the most striking finding of the entire project.
David eventually returns to Lanford and tells Darlene he wants to reenter his children's lives. After sleeping together, both Darlene and David consider reconciling until Roseanne tells Darlene the reason David said he left their marriage. She says it would be bad for their children, who resent David being an absent father. At Dan's urging, David agrees to get his life settled before seeing the kids again. In The Conners, David is working at Trader Joe's and has moved in with a free-spirited woman named Blue. Darlene is furious to discover that during the kids' first weekend staying with David, Blue allowed Harris' boyfriend to sleep over and she lost her virginity. David defensively says he was working and was unaware, but Darlene demands he be a more attentive father. David eventually breaks up with Blue because she wants children. David and Darlene began sleeping together again while Darlene is also in a relationship with Ben. Darlene decides she wants to be with Ben, and she and David finally agree to divorce. Ben, already knowing the two were seeing each other, breaks up with Darlene, though he eventually forgives her. David began seeing a therapist, and, during a joint session with Darlene, reveals he feels Darlene never treated him as an equal and caused him to leave her. When David was first introduced to the series, his name was Kevin, though it was subsequently changed to David. While applying for college, he uses his full name, David Maurice Healy. As a show inside joke, Roseanne comments in Season 6, "David's not even his real name.
=== Mixed === In mixed inhibition the inhibitor may bind to the enzyme whether or not the substrate has already bound. Hence mixed inhibition is a combination of competitive and noncompetitive inhibition. Furthermore, the affinity of the inhibitor for the free enzyme and the enzyme-substrate complex may differ. By increasing concentrations of substrate [S], this type of inhibition can be reduced (due to the competitive contribution), but not entirely overcome (due to the noncompetitive component). Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. Inhibitor binding to this allosteric site changes the conformation (that is, the tertiary structure or three-dimensional shape) of the enzyme so that the affinity of the substrate for the active site is reduced. These four types of inhibition can also be distinguished by the effect of increasing the substrate concentration [S] on the degree of inhibition caused by a given amount of inhibitor. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S].
Scarborough's drinking water is supplied by the R.C. Harris Filtration Plant at the foot of Victoria Park Avenue and the F. J. Horgan Filtration Plant. The F. J. Horgan Filtration Plant was built in 1979 and was formerly known as the 'Easterly Plant'. Upgrades completed in 2011 allow it to process up to 800 megalitres per day and it will also be the first plant to replace chlorine with ozone as its primary cleansing method. Wastewater for Scarborough is treated at the Highland Creek Treatment Plant. This plant was constructed in 1954 and started processing in 1956. It has undergone continual expansion to meet ongoing demand.
Sources: en.wikipedia.org
=== Fifth Republic === December 23, 1958: Decree amending various criminal provisions to introduce a fifth class of police contraventions; notably punishes passive soliciting. December 30, 1958: The term "birth allowance" replaces "maternity allowance," and the conditions for both that and the single wage allowance are modified. February 4, 1959: Ordinance on the general status of civil servants, which includes the principle of non-discrimination based on sex, except in certain exceptional cases, notably in the national police. April 9, 1960: Decree concerning the family record book. November 25, 1960: Ordinance on the fight against pimping. November 25, 1960: By decree, passive soliciting becomes a 3rd-class offense, active soliciting a 5th-class offense. December 2, 1960: France ratifies the United Nations Convention for the Suppression of the Traffic in Persons and of the Exploitation of the Prostitution of Others; the sanitary and social registry of prostitutes — created by law on April 24, 1946, and listing about 30,000 people in 1960 — is abolished. July 13, 1965: Law reforming matrimonial regimes: modification of the legal regime for marriages without a contract: the wife is free to manage her own property and pursue professional activity, no longer needing her husband's consent. September 29, 1965: Order establishing a study and liaison committee on women's labor issues. July 11, 1966: Law reforming adoption. December 30, 1966: Law on job protection in cases of maternity.
== Clinical significance == Clinical attachment loss is one of the three characteristic factors of periodontitis. In clinical practice, CAL is the primary feature assessed to diagnose periodontitis. Periodontitis is diagnosed when
Both copies of the affected gene must carry the same mutation (homozygous condition) for a person to be affected by an autosomal recessive disorder. An affected person usually has unaffected parents, each of whom carries one mutated gene and one normal gene (heterozygous condition) and is referred to as a genetic carrier; they may not have any symptoms. When both parents have the sickle cell trait, any given child has a 25% chance of sickle cell disease; a 25% chance of no sickle cell alleles, and a 50% chance of the heterozygous condition (see diagram). There are several different haplotypes of the sickle cell gene mutation, indicating that it may have arisen spontaneously in different geographic areas. The variants are known as Cameroon, Senegal, Benin, Bantu, and Saudi-Asian. These are clinically important because some are associated with higher HbF levels, e.g., Senegal and Saudi-Asian variants, and tend to have milder disease. The gene defect is a single nucleotide mutation of the β-globin gene, which results in the amino acid glutamic acid being substituted by valine at position 6 of the β-globin chain. Haemoglobin S with this mutation is referred to as HbS, as opposed to the normal adult HbA. Under conditions of normal oxygen concentration, this causes no apparent effects on the structure of haemoglobin or its ability to transport oxygen around the body. However, the deoxy form of HbS has an exposed hydrophobic patch, which causes HbS molecules to form long, inflexible chains.
Tompkins before the Supreme Court in 1938 George Smith (1916), pitcher for the Philadelphia Phillies Millard Bloomer (1920), Olympic fencer Harold Bloomer (1924), Olympic fencer Lou Gehrig* (1925), first baseman for the New York Yankees and member of the Baseball Hall of Fame Walter Koppisch (1925), football player for the New York Giants, member of the College Football Hall of Fame Ralph Furey (1928), football player, athletic director of Columbia University 1943–1968 Art Smith (1928), baseball player for the Chicago White Sox Fresco Thompson (1928), baseball player for the Philadelphia Phillies Hugh Alessandroni (1929), Olympic bronze medalist fencer Norman Armitage (1931), Olympic bronze medalist fencer; first person to be inducted into the USFA Hall of Fame Lou Bender (1932), pioneer player with the Columbia Lions and in early pro basketball; later a successful trial attorney George Gregory Jr.
Comorbid factors that can lead to ischemia are especially likely to contribute to chronic wounds. Such factors include chronic fibrosis, edema, sickle cell disease, and peripheral artery disease such as by atherosclerosis. Repeated physical trauma plays a role in chronic wound formation by continually initiating the inflammatory cascade. The trauma may occur by accident, for example when a leg is repeatedly bumped against a wheelchair rest, or it may be due to intentional acts. Heroin users who lose venous access may resort to 'skin popping', or injecting the drug subcutaneously, which is highly damaging to tissue and frequently leads to chronic ulcers. Children who are repeatedly seen for a wound that does not heal are sometimes found to be victims of a parent with Munchausen syndrome by proxy, a disease in which the abuser may repeatedly inflict harm on the child in order to receive attention. Periwound skin damage caused by excessive amounts of exudate and other bodily fluids can perpetuate the non-healing status of chronic wounds. Maceration, excoriation, dry (fragile) skin, hyperkeratosis, callus and eczema are frequent problems that interfere with the integrity of periwound skin. They can create a gateway for infection as well as cause wound edge deterioration preventing wound closure.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.